In a diabetic patient presenting with acute ischemic stroke, should alteplase be administered and what glucose management is recommended?

Alteplase Administration in Diabetic Patients with Acute Ischemic Stroke

Administer IV alteplase to diabetic patients with acute ischemic stroke within 0-3 hours of symptom onset without restriction; however, if presenting in the 3-4.5 hour window, alteplase should NOT be given if the patient has BOTH diabetes AND prior stroke history.

Alteplase Eligibility Based on Time Window

0-3 Hour Window

• Diabetes alone is NOT a contraindication 1
• Administer standard dose alteplase (0.9 mg/kg, maximum 90 mg over 60 minutes with 10% as initial bolus) to all otherwise eligible diabetic patients
• The 2018 AHA/ASA guidelines explicitly state Class I recommendation (Level of Evidence A) for treatment within 3 hours regardless of diabetes status 1

3-4.5 Hour Window

• Critical exclusion criterion: Patients with BOTH diabetes mellitus AND prior stroke history should NOT receive alteplase 1
• This represents a Class I contraindication (Level of Evidence B-R) 1
• Diabetes alone (without prior stroke) is acceptable for treatment in this window
• Other requirements for 3-4.5 hour window: age ≤80 years, NIHSS ≤25, not taking oral anticoagulants, no imaging evidence of ischemic injury >1/3 MCA territory 1

Common pitfall: Mistakenly withholding alteplase from all diabetic patients in the 3-4.5 hour window—only those with BOTH diabetes AND prior stroke are excluded.

Glucose Management Recommendations

Pre-Alteplase Glucose Requirements

• Minimum glucose threshold: >50 mg/dL required before administering alteplase (Class I, Level A) 1
• Patients with glucose <50 mg/dL should have glucose corrected before treatment
• Glucose >400 mg/dL: Treatment may be reasonable after normalization (Class IIb, Level C-LD) 1

Acute Glucose Management During Stroke

Target glucose range: 140-180 mg/dL 2, 3

• Initiate IV insulin protocol for:

  • Extreme or persistent hyperglycemia
  • Critically ill patients
  • Patients receiving thrombolytic therapy (first 24-48 hours) 3

• Avoid glucose <80 mg/dL—hypoglycemia may worsen brain injury 3

• After stabilization (24-48 hours), transition to subcutaneous basal-bolus insulin regimen 2, 3

Blood Pressure Management Post-Alteplase

• Maintain BP <180/105 mmHg for at least 24 hours after alteplase administration (Class I, Level B-NR) 1
• Pre-treatment: BP must be safely lowered to <185/110 mmHg before initiating alteplase 1

Evidence Supporting Treatment in Diabetic Patients

Research demonstrates that diabetic patients benefit from alteplase despite theoretical concerns:

• A 2011 study of 29,500 patients showed improved outcomes with thrombolysis in diabetic patients (OR 1.45,95% CI 1.30-1.62) comparable to non-diabetic patients 4
• The ENCHANTED trial (2018) found no increased risk of poor outcomes or symptomatic ICH in diabetic patients receiving alteplase 5
• No statistical justification exists for excluding diabetic patients from thrombolysis 4

Key Caveats

Hyperglycemia considerations:

• Admission hyperglycemia (≥140 mg/dL) is associated with increased symptomatic ICH risk and worse functional outcomes 6, 7
• Impaired fasting glucose (≥5.6 mmol/L or ~100 mg/dL) predicts unfavorable outcomes better than admission hyperglycemia alone 6
• Despite increased hemorrhagic risk, the benefit of alteplase still outweighs risks in hyperglycemic patients who meet eligibility criteria 4

Monitor closely for:

• Symptomatic intracranial hemorrhage (higher risk with hyperglycemia) 7
• Hypoglycemia during aggressive glucose control 3
• Blood pressure stability before and after alteplase 1